Skip to main content

Table 3 Events (cardiac death or heart transplantation) according to baseline characteristics (A) and blood pressure profile (B)

From: Prognostic value of systolic short-term blood pressure variability in systolic heart failure

A.

Baseline characteristics

Event (n = 70)

No event (n = 218)

p

Age, years

62 ± 12

59 ± 12

0.1

Male, n (%)

60 (86)

167 (77)

0.1

BMI

25.2 ± 3.6

26.2 ± 5.8

0.03

NYHA I &II, n (%)

18 (26)

135 (62)

<0.001

NYHA III&IV, n (%)

52 (74)

83 (38)

LVEF, %

27 ± 10

29 ± 9

0.2

Congestive HF, n (%)

39 (55)

83 (38)

<0.05

Diabetes, n (%)

19 (27)

42 (19)

0.16

Hypertension, n (%)

22 (31)

103 (47)

0.02

Ischemic, n (%)

34 (49)

97 (44)

0.5

Cockcroft, ml/min

64 ± 24

72 ± 28

<0.05

Heart rate, bpm

79 ± 15

79 ± 18

0.8

ACE inhibitor, n (%)

54 (77)

187 (86)

0.09

ARA2, n (%)

7 (10)

12 (6)

0.19

Spironolactone, n (%)

34 (49)

106 (49)

0.99

B-blockers, n (%)

38 (54)

141 (65)

0.12

Ca-channel blockers, n (%)

1 (1)

12 (6)

0.15

Nitride, n (%)

12 (17)

43 (20)

0.6

Diuretics, n (%)

66 (94)

182 (83)

0.02

B.

Blood pressure profile

Event (n = 70)

No event (n = 218)

p

SBP 24-h, mmHg

107 ± 15

111 ± 15

0.05

SBP daytime, mmHg

108 ± 16

113 ± 15

0.03

SBP nighttime, mmHg

104 ± 15

108 ± 17

0.13

DBP 24-h, mmHg

66 ± 9

69 ± 9

0.06

DBP daytime, mmHg

68 ± 9

71 ± 10

<0.05

DBP nighttime, mmHg

64 ± 10

66 ± 11

0.24

DIP, mmHg

3.4 ± 5

4.5 ± 7

0.23

PP daytime, mmHg

40 ± 11

42 ± 10

0.13

PP nighttime, mmHg

40 ± 11

42 ± 11

0.22

BPV daytime, mmHg

22 ± 6

24 ± 9

<0.05

BPV nighttime, mmHg

17 ± 6

18 ± 8

0.4

  1. ACE angiotensin converting enzyme, ARA2 angiotensin 2 receptor antagonist, BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York Heart Association, BPV blood pressure variability, DBP diastolic blood pressure, PP pulse pressure